Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 6Rectal Neoplasms 5Colonic Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 4Brain Neoplasms 4Ovarian Neoplasms 3Melanoma 3Glioblastoma 3Breast Neoplasms 3Advanced Solid Tumor 3Stomach Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Gliosarcoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms, Male 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Spinal Cord Neoplasms 1Sezary Syndrome 1Rhabdoid Tumor 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Neoplasms, Plasma Cell 1

Interventions

cediranib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Tumor × cediranib × Clear all
NCT00502060 2009-05-14

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

AstraZeneca

Phase 1 Completed
65 enrolled

Advanced Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡